Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity

Flachenecker, Peter; Henze, Thomas; K. Zettl, Uwe

doi:10.1159/000357427

Public

Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity

Shared by NobleBlocks on Jan 1, 2014 • 12:00 AM UTC

Authors:

Peter Flachenecker

Thomas Henze

Uwe K. Zettl

Abstract

<b><i>Background:</i></b> Nabiximols (Sativex®), a cannabinoid-based oromucosal spray, is an add-on therapy for patients with moderate to severe multiple sclerosis spasticity (MSS) resistant to other medications. The primary objective was to provide real-life observational data of clinical experienc...

Discussions